A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
12/2011
12/08/2011	WO2011151434A1 Novel compounds, pharmaceutical composition and methods for use in treating metabolic disorders
12/08/2011	WO2011151362A1 Nitrate and diazeniumdiolate derivatives of pioglitazone
12/08/2011	WO2011151358A1 2 -amino- pyrimidine derivatives useful as inhibitors of jnk
12/08/2011	WO2011151357A1 Inhibitors of jnk
12/08/2011	WO2011150682A1 4-hydroxyquinoline-3-amide derivatives and preparation methods and uses thereof
12/08/2011	WO2011150516A1 Diagnostic, screening and therapeutic applications of ocab-based tools
12/08/2011	WO2010128401A9 Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
12/08/2011	US20110301242 Inhibitors of Cathepsin S for Prevention or Treatment of Obesity-Associated Disorders
12/08/2011	US20110301235 Organoselenium compounds and uses thereof
12/08/2011	US20110301231 Lipase inhibiting composition
12/08/2011	US20110301215 Inhibitors of plasma kallikrein
12/08/2011	US20110301207 Methods and sustained release nicotinic acid compositions for treating hyperlipidemia
12/08/2011	US20110301202 Spla2 inhibitor conjugate compounds and methods of use
12/08/2011	US20110301200 Thyroid receptor ligands
12/08/2011	US20110301191 Methods of treatment using selective 5-ht2a inverse agonists
12/08/2011	US20110301182 Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
12/08/2011	US20110301180 Reducing Platelet Activation, Aggregation and Platelet-Stimulated Thrombosis or Blood Coagulation by Reducing Mitochondrial Respiration
12/08/2011	US20110301172 Combination of dpp-iv inhibitor, ppar antidiabetic and metmorformin
12/08/2011	US20110301171 Inhibitors of JNK
12/08/2011	US20110301170 Inhibitors of JNK
12/08/2011	US20110301158 Aryl carbonyl derivatives as therapeutic agents
12/08/2011	US20110301157 Bicyclic amides as kinase inhibitors
12/08/2011	US20110301156 Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions
12/08/2011	US20110301155 Indazole compounds for activating glucokinase
12/08/2011	US20110301149 Compositions and methods for treating alcohol use disorders, pain and other diseases
12/08/2011	US20110301148 Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof
12/08/2011	US20110301146 Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives
12/08/2011	US20110301143 Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
12/08/2011	US20110301140 Pyridine Carboxamide orexin Receptor Antagonists
12/08/2011	US20110301133 Compositions of protein receptor tyrosine kinase inhibitors
12/08/2011	US20110301128 Pyrrole Derivatives As Pharmaceutical Agents
12/08/2011	US20110301112 Fused ring thrombin receptor antagonists
12/08/2011	US20110301103 Methods of Treatment
12/08/2011	US20110301097 Oral Administration Of Therapeutic Agent Coupled To Transporting Agent
12/08/2011	US20110301096 Prodrug of an ice inhibitor
12/08/2011	US20110301091 Compositions and methods for reducing the signs of aging of the skin
12/08/2011	US20110301085 Protein hydrolysate and plant sterol containing composition for improving serum lipid profile and preventing atherosclerosis
12/08/2011	US20110301084 Protracted Exendin-4 Compounds
12/08/2011	US20110301083 Conjugate based systems for controlled drug delivery
12/08/2011	US20110301082 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
12/08/2011	US20110301081 Long-acting formulations of insulins
12/08/2011	US20110301080 Pharmaceutical compositions
12/08/2011	US20110301079 Neuromedin u receptor agonists and uses thereof
12/08/2011	US20110301077 Method for production of lactoferrin
12/08/2011	US20110300246 Herbal Extracts for Treatment of Diabetic Complications and Oxidative Stress
12/08/2011	US20110300244 Water-soluble extracts of artemisia dracunculus (tarragon) for improvement of glucose metabolism
12/08/2011	US20110300240 Cajanus extracts and glucosamine for inflammatory disorders
12/08/2011	US20110300220 Solid calcium lactate in substantially spherical form
12/08/2011	US20110300209 Modified release solid pharmaceutical compositions of trimetazidine and process thereof
12/08/2011	US20110300199 Peptides used in the treatment and/or care of the skin, mucous membranes and/or scalp and their use in cosmetic or pharmaceutical compositions
12/08/2011	US20110300190 Compound, composition and uses thereof
12/08/2011	US20110300175 Composition for promoting control of total and ldl cholesterol, and/or weight loss and/or thermogenesis
12/08/2011	US20110300165 Substituted isoxazole compounds
12/08/2011	US20110300160 Sulfation of wnt pathway proteins
12/08/2011	US20110300155 Modulating xrn2
12/08/2011	US20110300149 Ljungan virus
12/08/2011	US20110300145 Interferon Alpha Antibodies And Their Uses
12/08/2011	US20110300143 Prenatal enzyme replacement therapy
12/08/2011	US20110300142 Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants
12/08/2011	US20110300136 Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
12/08/2011	US20110300135 Method and formulation for reducing aggregation of a macromolecule under physiological conditions
12/08/2011	US20110300120 Oligosaccharide-protein conjugates
12/08/2011	US20110300119 Methods of enriching and using regulatory t cells
12/08/2011	US20110300117 Novel Lactobacillus Strain, Composition and Use Thereof for Improving the Syndrome of Diabetes and Complication Thereof
12/08/2011	US20110300066 Combination Therapy With Anti-CD74 Antibodies Provides Enhanced Toxicity to Malignancies, Autoimmune Disease and Other Diseases
12/08/2011	CA2836413A1 Cellular constituents from bacteroides, compositions thereof, and therapeutic methods employing bacteroides or cellular constituents thereof
12/08/2011	CA2801770A1 Methods of treatment
12/08/2011	CA2801579A1 Methods for treatment of nephrotic syndrome and related conditions
12/08/2011	CA2801454A1 Nitrate and diazeniumdiolate derivatives of pioglitazone
12/08/2011	CA2801417A1 Optically active dibenzylamine derivative, and method for preparing thereof
12/08/2011	CA2801166A1 Feed composition comprising a mineral complex and methods of using the mineral complex
12/08/2011	CA2801162A1 Diagnostic, screening and therapeutic applications of ocab-based tools
12/08/2011	CA2801030A1 Crystal of thienopyrimidine derivative
12/08/2011	CA2799817A1 Inhibitors of jnk
12/08/2011	CA2799328A1 2 -amino- pyrimidine derivatives useful as inhibitors of jnk
12/07/2011	EP2392594A1 N-terminally monopegylated polypeptides and process for their preparation
12/07/2011	EP2392573A1 Quinoline derivative
12/07/2011	EP2392572A1 Substituted diazepan compounds as orexin receptor antagonists
12/07/2011	EP2392340A1 Novel lactobacillus strain, composition and use thereof for improving the syndrome of diabetes and complication thereof
12/07/2011	EP2392338A1 Prophylactic or therapeutic agent for diseases associated with abnormal bone metabolism
12/07/2011	EP2392322A2 Dosing regimes for trans-clomiphene
12/07/2011	EP2391620A1 Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
12/07/2011	EP2391616A1 Carboxamide compounds and methods for using the same
12/07/2011	EP2391609A1 Key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof
12/07/2011	EP2391605A1 Scriptaid isosteres and their use in therapy
12/07/2011	EP2391360A2 Method of synergistically enhancing the therapeutic efficacy and safety of medications through a combination therapy
12/07/2011	EP2391359A1 Dpp-iv inhibitors for treatment of diabetes in paediatric patients
12/07/2011	EP2391228A1 Composition comprising chicoric acid and/or derivatives thereof
12/07/2011	EP1660467B1 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazole compounds useful as protein kinase inhibitors
12/07/2011	EP0515460B2 Docosahexaenoic acid, methods for its production and compounds containing the same
12/07/2011	CN1494425B 用作治疗剂的羧酰胺衍生物 As therapeutic agents carboxamide derivatives
12/07/2011	CN102272306A 抗-Siglec-15抗体 Anti -Siglec-15 antibody
12/07/2011	CN102272163A 瘦素和瘦素类似物结合物及其用途 Leptin and analogue conjugates and their use
12/07/2011	CN102272136A 作为用于糖尿病的治疗或预防的二肽基肽酶-Ⅳ抑制剂的氨基四氢吡喃 For the treatment or prevention of dipeptidyl peptidase inhibitors for diabetes -Ⅳ aminotetrahydropyran
12/07/2011	CN102272135A 唑并吡咯酮黑色素浓集激素受体-1拮抗剂 Razolo pyrrolone melanin concentrating hormone receptor-1 antagonist
12/07/2011	CN102272128A Atp-结合盒转运蛋白的调节剂 Atp- binding cassette transporter protein modifier
12/07/2011	CN102272127A Atp-结合盒转运蛋白调节剂 Atp- binding cassette transporter protein modifiers
12/07/2011	CN102272120A 生物活性酰胺 Bioactive amides
12/07/2011	CN102271701A 具有脂类动员性质的糖蛋白及其治疗用途 Glycoprotein lipid mobilizing its therapeutic use have properties
12/07/2011	CN102271673A 尽管接受包括dpp-iv抑制剂的二甲双胍治疗但血糖控制仍不足的患者中的糖尿病的治疗 Including treatment of patients despite receiving metformin dpp-iv inhibitor but still insufficient glycemic control in diabetes

1 ... 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 ... 1298